● neutral
Impact
PhasePhase 3 (registrational)
Time to marketIf Phase 3 RESTORE succeeds, a potential FDA submission could occur in 2028-2029, assuming enrollment completes and the 16-week treatment period yields positive results. Breakthrough Therapy designation may accelerate FDA review.
NVG-291 Updated Nov 13
What to watch
The next major catalyst is the Phase 3 RESTORE topline data readout, likely in late 2027 or 2028 given enrollment just began in October 2026. Positive data would validate NVG-291 as a first-in-class neuroreparative therapy for a large unmet need with no approved pharmacologic alternatives; negative data would be devastating for this single-asset company. Interim enrollment updates or any early efficacy signals could also move the stock.
Bull case
- FDA granted Breakthrough Therapy designation on November 12, 2026, based on positive Phase 1b/2a chronic cohort data, which can expedite development and expedited review.
- Positive topline data from the Phase 1b/2a CONNECT SCI study showed functional hand use improvements in chronic spinal cord injury patients, with no serious adverse events or treatment discontinuations.
- Successful End-of-Phase 2 meeting with FDA alignment on the Phase 3 RESTORE study design, including agreement on the primary endpoint (GRASSP Quantitative Prehension at Week 12).
Bear case
- Phase 3 RESTORE study just began dosing (October 2026); enrollment and topline data are likely 12-18+ months away, creating a long binary wait with no near-term catalyst.
- The company is a single-asset developer (NVG-291 is its only pipeline drug), making the stock extremely sensitive to any negative development.
- NervGen raised US$60M in a dilutive May 2026 offering priced at $2.50/share, and the stock has fallen roughly 62% year-to-date before the recent Breakthrough Therapy bounce.